The Poly (ADP-ribose) polymerase (PARP) family has many essential functions in cellular
processes, including the regulation of transcription, apoptosis and the DNA damage …

Background Poly (ADP-ribose) polymerase (PARP) inhibitors have shown efficacy and
acceptable safety in a range of neoplasms, particularly in ovarian cancers. However, some …

Background Olaparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, has previously
been shown to extend progression-free survival versus placebo when given to patients with …

Epithelial ovarian cancer is the leading cause of death from gynecologic cancer in the
United States and is the country's fifth most common cause of cancer mortality in women. A …

Ovarian cancer remains one of the most challenging malignancies to treat. Targeted
therapies such as poly (ADP-ribose) polymerase (PARP) inhibitors have emerged as one of …

PURPOSE A phase II study (ClinicalTrials. gov identifier: NCT00628251) showed activity of
olaparib capsules versus pegylated liposomal doxorubicin in patients with germline BRCA …

Epithelial ovarian cancer is the leading cause of death from gynecologic cancer in the
United States, with less than half of patients living> 5 years from diagnosis. A major …

Inhibition of poly (ADP-ribose) polymerase (PARP) activity induces synthetic lethality in
mutated BRCA1/2 cancers by selectively targeting tumor cells that fail to repair DNA double …

Highlights•Platinum-based chemotherapy remains the most active treatment for ovarian
cancer.•Platinum should not be withheld after response to last platinum and a treatment-free …

Olaparib, niraparib, rucaparib, and talazoparib are poly (ADP-ribose) polymerase (PARP)
inhibitors approved for the treatment of ovarian, breast, pancreatic, and/or prostate cancer …